1. Home
  2. MDIA vs LUNG Comparison

MDIA vs LUNG Comparison

Compare MDIA & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mediaco Holding Inc.

MDIA

Mediaco Holding Inc.

HOLD

Current Price

$0.77

Market Cap

50.0M

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.28

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDIA
LUNG
Founded
2019
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Industrial Specialties
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.0M
57.9M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
MDIA
LUNG
Price
$0.77
$1.28
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
116.5K
346.7K
Earning Date
05-19-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
$133,336,000.00
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
39.52
8.01
52 Week Low
$0.54
$1.13
52 Week High
$1.64
$3.88

Technical Indicators

Market Signals
Indicator
MDIA
LUNG
Relative Strength Index (RSI) 45.72 39.78
Support Level $0.59 $1.20
Resistance Level $0.99 $1.67
Average True Range (ATR) 0.15 0.10
MACD -0.00 -0.03
Stochastic Oscillator 10.99 14.29

Price Performance

Historical Comparison
MDIA
LUNG

About MDIA Mediaco Holding Inc.

MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming, and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales, events including sponsorships and ticket sales, licensing, and syndication. The company has two business segments: the Audio segment and the Video segment. The company generates the majority of its revenue from the Audio segment.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: